Table 1. Association of ASPM expression levels with different clinicopathologic characteristics in EOC.
| Clinicopathologic | ASPM expression, n (%) | P value | |
|---|---|---|---|
| Low count | High count | ||
| Age, years | 0.133 | ||
| ≤50 | 25 (65.8) | 18 (48.6) | |
| >50 | 13 (34.2) | 19 (51.4) | |
| Lymph node metastasis | 0.030 | ||
| N0 | 37 (97.4) | 29 (78.4) | |
| N1 | 1 (2.6) | 8 (21.6) | |
| TNM stage | 0.008 | ||
| Stage I | 31 (81.5) | 19 (51.4) | |
| Stage II | 2 (5.3) | 1 (2.7) | |
| Stage III | 5 (13.2) | 17 (45.9) | |
| Histologic grade | <0.0001 | ||
| Grade 1 | 10 (26.3) | 0 (0.0) | |
| Grade 2 | 16 (42.1) | 11 (29.7) | |
| Grade 3 | 12 (31.6) | 26 (70.3) | |
P values were calculated by comparing the expression of ASPM with different clinical variables respectively using a chi-square test. P<0.05 was considered statistically significant. ASPM, spindle-like microcephaly-associated protein; TNM, tumor-node-metastasis; EOC, epithelial ovarian cancer.